Literature DB >> 3177256

Reirradiation of recurrent tumors in the head and neck.

J Pomp1, P C Levendag, W L van Putten.   

Abstract

From 1971 to 1980, 55 patients were reirradiated in the Dr. Daniel den Hoed Kliniek for a recurrent cancer in the head and neck. For all patients considered, the primary treatment consisted of full course radiation therapy (RT) only; the recurrent tumors were irradiated with external and/or interstitial radiation therapy. In some of these patients, the reirradiation was combined with surgery and/or chemotherapy. A poor overall survival was found, i.e., after 5 years only 20% of the patients are still alive. Although the patients with a recurrent tumor of the nasopharynx seem to fare slightly better, no statistically significant difference was found for the different sites in the head and neck. A trend towards a somewhat better survival was observed for subsets of patients for whom either the reirradiation was combined with surgery or for whom the time period elapsed between the primary treatment and the initiation of the second irradiation was more than 12 months. Moreover, best local control was seen in recurrent tumors reirradiated by high doses of RT; i.e., with 50 Gy or more, a local control rate of 48% was obtained. Future treatment strategies towards a better local control and survival are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3177256     DOI: 10.1097/00000421-198810000-00007

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  8 in total

1.  Outcome after re-irradiation of head and neck cancer patients.

Authors:  Nele Platteaux; Piet Dirix; Bianca Vanstraelen; Sandra Nuyts
Journal:  Strahlenther Onkol       Date:  2010-12-22       Impact factor: 3.621

2.  Role of stereotactic body radiotherapy for symptom control in head and neck cancer patients.

Authors:  Luluel Khan; Michael Tjong; Hamid Raziee; Justin Lee; Darby Erler; Lee Chin; Ian Poon
Journal:  Support Care Cancer       Date:  2014-10-09       Impact factor: 3.603

3.  The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.

Authors:  Jean-Claude M Rwigema; Dwight E Heron; Robert L Ferris; Regiane S Andrade; Michael K Gibson; Yong Yang; Cihat Ozhasoglu; Athanassios E Argiris; Jennifer R Grandis; Steven A Burton
Journal:  Am J Clin Oncol       Date:  2011-08       Impact factor: 2.339

4.  CT-guided iodine-125 seed permanent implantation for recurrent head and neck cancers.

Authors:  Yu L Jiang; Na Meng; Jun J Wang; Ping Jiang; Hui Sh Yuan; Chen Liu; Ang Qu; Rui J Yang
Journal:  Radiat Oncol       Date:  2010-07-30       Impact factor: 3.481

5.  A retrospective, deformable registration analysis of the impact of PET-CT planning on patterns of failure in stereotactic body radiation therapy for recurrent head and neck cancer.

Authors:  Kyle Wang; Dwight E Heron; John C Flickinger; Jean-Claude M Rwigema; Robert L Ferris; Gregory J Kubicek; James P Ohr; Annette E Quinn; Cihat Ozhasoglu; Barton F Branstetter
Journal:  Head Neck Oncol       Date:  2012-04-19

6.  Re-irradiation of unresectable recurrent head and neck cancer: using Helical Tomotherapy as image-guided intensity-modulated radiotherapy.

Authors:  Songmi Jeong; Eun Jung Yoo; Ji Yoon Kim; Chi Wha Han; Ki Jun Kim; Chul Seung Kay
Journal:  Radiat Oncol J       Date:  2013-12-31

7.  An investigation of 125I seed permanent implantation for recurrent carcinoma in the head and neck after surgery and external beam radiotherapy.

Authors:  Lihong Zhu; Yuliang Jiang; Junjie Wang; Weiqiang Ran; Huishu Yuan; Chen Liu; Ang Qu; Ruijie Yang
Journal:  World J Surg Oncol       Date:  2013-03-08       Impact factor: 2.754

Review 8.  Stereotactic body radiation therapy in the re-irradiation situation--a review.

Authors:  Frederick Mantel; Michael Flentje; Matthias Guckenberger
Journal:  Radiat Oncol       Date:  2013-01-05       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.